Dataset opportunity
Robocath — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Robocath, usable for Diagnostic AI and Computer Vision.
Score
59.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
42%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
$$$ — high AI buyer demand
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-04
Can surgical robots fly? SS Innovations discusses challenges, solutions
therobotreport.com ↗ - 📰press2026-06-04
Medtronic seeks clearance for Hugo surgical robot in more indications
medtechdive.com ↗ - 📰press2026-06-02
Petal Surgical adds more funding for incisionless surgical robot
therobotreport.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Public web signals indicate Robocath (healthcare sector) holds a medical imaging dataset (image). Detected via iot_data, medical_records evidence across 1 sources. Dominant evidence: medical_records. ⚠ Diligence (valuable data, access to negotiate): Data generated during medical procedures, potentially containing patient information.; Subject to GDPR and other medical data regulations.; Data ownership split between Robocath (device performance) and healthcare providers/patients (procedural/patient data).; Now a subsidiary of Stereotaxis, requiring coordination with the parent company. · corporate: acquired of Stereotaxis.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This opportunity offers access to proprietary medical imaging data, directly generated by Robocath's R-One+™ robotic system during critical interventional cardiology procedures like coronary angioplasties. This unique dataset provides unparalleled, real-world clinical insights, making it exceptionally valuable for diagnostic AI development and training. Given the high demand from Medical-AI and diagnostic-imaging companies, this data is poised to accelerate innovation in a rapidly evolving healthcare sector, offering a competitive edge. Its rarity further underscores its strategic importance.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume46
2 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand92
The global AI in medical imaging market, which relies heavily on such datasets for diagnostic AI, is projected to grow at a CAGR of 35.11% from 2026 to 2033, reaching $20.2 billion by 2033.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, acquired of Stereotaxis
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength50
2 evidence types, 2 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence45
acquired of Stereotaxis
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 3 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ review — Robocath is not a good target because it was recently acquired by Stereotaxis, a publicly traded company, which moves it away from the ideal independent SME profile and into the category of larger, more established groups that the ICP aims to exclude. Issues: Robocath was acquired by Stereotaxis, a publicly traded company, on April 15, 2026, which conflicts with the ICP's exclusion of 'giants/opaque groups' and the f; Data ownership and strategy may now be dictated by the parent compa
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
IoT / sensor data
This evidence indicates the availability of Time Series data, detailing the operational performance and precise assistance of the R-One+™ robotic assistance platform during medical procedures, offering critical operational insights for AI-driven system optimization and workflow analysis.
Medical records / imaging
This evidence confirms the existence of medical imaging data captured during complex coronary angioplasties performed with the R-One+™ robotic solution, providing a highly specific and proprietary dataset crucial for training advanced diagnostic AI models in cardiovascular interventions.
Coverage
Scanned sources
Deliverable
Premium dataset report
Robocath Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: $$$ — high AI buyer demand. Investment score 59.9/100 (confidence 0.42). Recommended action: Data Sharing Agreement.